Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

Shares of NASDAQ:NTLA opened at $9.30 on Thursday. The company has a market cap of $962.71 million, a P/E ratio of -1.71 and a beta of 1.97. Intellia Therapeutics, Inc. has a 52 week low of $8.30 ...

Cathie Wood’s ARK ETFs have disclosed their daily trades for Friday, March 14th, 2025, with significant transactions across a ...

View Our Latest Analysis on NTLA Intellia Therapeutics Trading Up 4.8 % Shares of NTLA opened at $9.58 on Tuesday. The firm’s 50-day moving average price is $10.30 and its 200-day moving average ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

and Intellia. Dr Tang has served as a consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, WhiteSwell, Boston Scientific, CardiaTec Biosciences, Bristol Myers Squibb ...

Furthermore, emerging gene editing approaches, such as Intellia Therapeutics (NASDAQ ... The current estimates of the ATTR-CM patient population may be conservative. Some analysts believe the ...